MP34-19 clinical efficacy and safety of silodosin in women with lower urinary tract symptoms: a 12-week prospective study
Abstract
RESULTS: A total of 10 patients were included in this study. The median age was 75.5 years (IQR: 70.8 e 78.5), with a median follow-up of 26 months (IQR: 12 e 35.8). Intraoperative cystoscopy consistently showed whitish, fi brotic prostate changes, with unusually hard tissue resembling an "eraser" compared with typical BPH adenoma tissue (Figure 1A). The surrounding tissues did not bulge into the lumen during resection but maintained their position (Figure 1B). Signi fi cant improvements were observed in IPSS, LQ, OABSS, Qmax, and PVR postoperatively (p [ 0.005, 0.001, 0.043, 0.011, and 0.021, respectively). De novo stress urinary incontinence was observed in 2 cases, both of which had preoperative urinary retention and improved within six months postoperatively. One case required hematoma evacuation for gross hematuria. No other complications above Clavien-Dindo grade II were reported. CONCLUSIONS: Due to the tissue characteristics after brachytherapy, BraTURP requires tailored approaches distinct from typical BPH TURP. This study demonstrates that BraTURP effectively relieves symptoms with a low complication rate. However, given the rarity and small number of cases, further studies are needed to optimize it.
Read the paper
Related studies
- Antioxidant efficacy and the upregulation of Nrf2-mediated HO-1 expression by (+)-lariciresinol, a lignan isolated from Rubia philippinensis, through the activation of p38
- Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens
- Therapeutic Potential of Mesenchymal Stem Cells (MSCs) and MSC-Derived Extracellular Vesicles for the Treatment of Spinal Cord Injury
- The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model
- Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer
- In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.